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Abstract 
Many patients on haemodialysis retain significant residual renal function (RRF) but currently 
measurement of RRF in routine clinical practice can only be achieved using inter-dialytic 
urine collections to measure urea and creatinine clearances. Urine collections are difficult 
and inconvenient for patients and staff, and therefore RRF is not universally measured. 
Methods to assess RRF without reliance on urine collections are needed since RRF 
provides useful clinical and prognostic information and also permits the application of 
incremental haemodialysis techniques. Significant efforts have been made to explore the 
use of serum based biomarkers such as cystatin C, β-trace protein and β2-microglobulin to 
estimate RRF. This article reviews blood-based biomarkers and novel methods using 
exogenous filtration markers which show potential in estimating RRF in haemodialysis 
patients without the need for urine collection. 
  
Introduction 
 
Many haemodialysis (HD) patients retain useful residual renal function (RRF) for a number of 
years following embarking on dialysis treatment. RRF is of significant importance to dialysis 
patients and provides numerous clinical benefits including improved blood pressure control, 
reduced ultrafiltration requirements and improved clearance of uraemic toxins (1,2). Loss of 
RRF is a strong predictor of mortality and there are compelling reasons to preserve RRF (3). 
Knowledge of RRF not only provides useful prognostic information to clinicians but there has 
also been a resurgent interest to incorporate RRF in the haemodialysis prescription as part of 
‘incremental dialysis’ with suggestions that it may help to preserve RRF (4,5). However, 
measurement of RRF is difficult since extensively validated blood-based biomarkers of RRF 
are currently not available and ‘gold-standard’ measures of renal function such as inulin 
clearance are impractical for routine clinical use. The current method of estimating RRF in 
haemodialysis patients recommended by European and American Guidelines require a 
prolonged inter-dialytic urine together with blood sampling to measure renal urea clearance 
(KRU) and/or creatinine clearance (6,7). Since urea clearance underestimates GFR and 
creatinine clearance overestimates GFR, the average of urea and creatinine clearance is used 
to estimate GFR. In haemodialysis patients, mean of urinary urea and creatinine clearance 
correlate well with urinary inulin clearance (8). However, timed urine collections are difficult for 
patients and dialysis staff and are unreliable even in well-controlled conditions (9,10). 
Therefore most HD centres do not routinely measure RRF and its presence is largely ignored. 
This represents a major barrier for nephrologists who are interested in using incremental 
dialysis in HD patients. Thus, there is a growing need for accurate and validated methods to 
measure RRF in HD patients without reliance on urine collection. This paper reviews potential 
novel methods of measuring RRF without urine collection in HD patients. 
 
Endogenous markers of RRF 
 
Although the kidneys perform several important physiological functions, GFR is still 
considered the best overall measurement of kidney function (11). GFR is defined as the 
volume of plasma cleared of an ideal substance per unit time (mL/min) (12). Serum urea and 
creatinine by themselves cannot be used to estimate RRF since both are small molecules (60 
and 113 daltons respectively) and easily removed during dialysis, therefore levels fluctuate 
significantly between dialysis sessions. Efforts have been directed at exploring the use of low 
molecular weight proteins or “middle molecules” that are not easily removed by dialysis to 
estimate RRF. A large number of biomarkers have been explored (table 1). Cystatin C, β2-
microglobulin and β-trace protein have been the most extensively examined. 
Cystatin C 
 
Cystatin C is a cationic cysteine proteinase produced by all nucleated cells (13). It is freely 
filtered by the glomerulus and almost completely reabsorbed and metabolised by the proximal 
tubules (14). Cystatin C levels are generally constant – except with steroid use (15) and thyroid 
dysfunction (16), its levels are not influenced by muscle mass, diet, gender, ethnicity, 
inflammation or infection. Thus cystatin C is proposed to be a useful marker of GFR (13), 
particularly to characterise those with mild kidney disease (eGFR 45-59 mL/min/1.73m2) 
because of its superior ability to detect reductions in GFR in in the so-called “creatinine-blind” 
range(9,17,18). At 13.3 kDa, cystatin C is partially removed by dialysis, however kinetic 
studies of cystatin C in the HD population show that levels rapidly rebound to 95% of its pre-
dialysis levels within 12 hours after dialysis (19). Hoek et al (20) developed equations based 
on a serum cystatin C to estimate RRF in HD and PD patients, which were validated against 
measured GFR using urinary urea and creatinine clearances. The equations showed non-
significant bias from measured GFR. However, other studies found that cystatin C based 
equations overestimated measured GFR (21,22) which may lead to inappropriate reduction of 
dialysis if an incremental haemodialysis prescription is applied. Additionally, these equations 
did not correlate with measured GFR using EDTA clearance techniques (22). There is also 
significant intra- and inter-individual variation of cystatin C, with predominance of non-renal 
clearance at low levels of GFR (19,23,24). Thus in HD patients, this is likely to lead to 
significant errors and cystatin C by itself may not be sufficient to accurately estimate RRF. 
 
Beta-2 microglobulin (β2M) 
 
β2M has a molecular weight of 11.8 kDa (25) and is a component of the class 1 major 
histocompatibility antigens present on all nucleated cells (26). Its levels accumulate in kidney 
failure and historically β2M has been implicated in the pathogenesis of dialysis-related amyloid 
(27). It is almost exclusively eliminated by kidneys and undergo glomerular filtration followed 
by reabsorption and catabolism by the proximal tubule cells (27). RRF is a significant 
determinant of β2M (28–30) and appears to have greater influence over β2M levels than the 
effect of enhanced convective clearance provided by haemodiafiltration (29,31) or peritoneal 
dialysis (26,32). However, β2M levels may increase with conditions such as malignancy, lupus 
(33,34) and inflammation – commonly seen in many dialysis patients, and can also be affected 
by age and gender (35). Large inter-individual variation especially in those with minimal RRF 
(36) and non-specific elevation may limit its use a marker of RRF when used in isolation. β2M 
is  a better predictor of RRF (measured by urinary and creatinine clearances) than cystatin C 
in HD patients although the constructed β2M predictive equations could only explain 68% of 
the variance of measured GFR further supporting the notion that β2M by itself may not be able 
to accurately predict RRF (36).  
 
Beta-trace protein (βTP) 
 
βTP, also known as lipocalin type prostaglandin D synthase, is a glycoprotein with a molecular 
mass between 23-29 kDa that has been used as a marker of cerebrospinal fluid leakage (37). 
It is expressed by the brain, retina, testes, heart and kidney (38) and is primarily excreted by 
the kidneys (39). It accumulates in renal failure and serum βTP levels correlate well with 
residual urine volumes in haemodialysis (40). βTP is a relatively large molecule and not 
removed by conventional low- or high-flux dialysis (40), although there is some clearance by 
haemodiafiltration (40), its levels are not significantly altered and do not appear to rise 
significantly during the inter-dialytic period (21). Non-renal elimination appears to be minimal 
(39). Due to these properties, βTP shows promise as a marker of kidney function in dialysis 
patients. We (41) and others (21) have constructed equations based on βTP to estimate RRF 
in haemodialysis patients and compared this with measured GFR using urinary urea and 
creatinine clearances. Both studies found that combining βTP with β2M in a predictive 
equation performed better than either biomarker alone. Shafi et al additionally measured 
cystatin C in their study cohort but found that after incorporating all three biomarkers (βTP, 
β2M and cystatin C) together in an equation, coefficients for cystatin C became insignificant. 
Both equations slightly underestimated KRU and GFR but demonstrated high diagnostic 
accuracy to identify patients with KRU>2ml/min/1.73m2, the threshold set by KDOQI (Kidney 
Disease Outcomes Quality Initiative) for which sufficient RRF is present to allow dialysis Kt/V 
targets to be reduced providing this does not compromise ultrafiltration targets. However, bias 
between measured and estimated KRU was approximately ~0.5ml/min for both studies with 
relatively wide limits of agreement which suggests that the βTP and β2M-based estimating 
equations may not be accurate enough to replace urine collections for more precise estimates 
of RRF. Furthermore, estimating equations underestimated the decline in kidney function over 
time (21), which may lead to inappropriate reduction of dialysis requirements if an incremental 
haemodialysis regime is used. βTP-based equations have not yet been validated against 
“gold-standard” methods of measuring kidney function such as inulin clearance. In addition, 
further work is required to establish laboratory standards for βTP to ensure consistency in 
inter- and intra-laboratory measurements (42).  
 
Other markers of kidney function 
 
There are a number of potential novel biomarkers that are proposed to be promising markers 
of kidney function, however their ability to estimate RRF in the HD setting have not been 
rigorously examined (table 1). 
 
Neutrophil Gelatinase-associated Lipocalin (NGAL) 
 
Similar to βTP, NGAL is a member of the lipocalin family and is a 25 kDa protein bound to 
neutrophil gelatinase (43,44). NGAL is synthesised in the bone marrow during granulopoiesis 
and stored in neutrophil granules (45,46). NGAL expression is upregulated following acute 
kidney injury (AKI) (47) and substantial amounts are released into the blood and urine from 
injured tubular cells (48). NGAL levels typically increase preceding the rise in creatinine 
leading to many advocating its use a biomarker to identify early stages of AKI (44,49–52). 
NGAL is freely filtered by the glomerulus and avidly re-absorbed by the proximal tubules. 
Reduction in GFR leads to its accumulation in the systemic circulation (53) and cross-sectional 
studies show that NGAL levels correlate well with estimated GFR (48,54,55) and measured 
GFR using ioversol clearance (56). Studies of NGAL in dialysis patients are limited although 
NGAL levels are significantly elevated in HD patients (57,58) and one study found RRF to be 
a significant determinant of NGAL (58). However, NGAL release may be triggered by systemic 
inflammation, infection or the haemodialysis procedure (57–59). NGAL levels also differ 
significantly depending on underlying renal pathology independent of GFR (54). Thus, NGAL 
may not be a specific enough to estimate RRF as it is prone to influence by a number of extra-
renal factors. 
 
Tumour markers – Chromogranin A and Tumour-associated trypsin inhibitor  
 
Two tumour markers have shown a close relationship with kidney function and could 
potentially be utilised as a marker of RRF in patients without malignancy. Chromogranin A 
(CgA) is a 49 kDa protein synthesised in the chromaffin granules of the neuroendocrine cells 
(60). CgA levels are increased in those with neuroendocrine tumours, phaeochromocytomas, 
neuroblastomas, small cell lung cancer and prostate cancers (60,61). Levels of CgA was found 
to have a close relationship with renal function using 99mTc-DTPA clearance studies. (62), CgA 
levels increases significantly as GFR falls <60mL/min and rises exponentially with 
GFR<20mL/min. However, the rise in CgA can be variable and wide confidence intervals were 
observed in those with low GFR suggesting marked inter-individual variation which may limit 
its predictive accuracy in the dialysis population.  
 
Tumour-associated trypsin inhibitor (TATI) is a 6.2 kDa protein and is a tumour marker for 
ovarian, pancreatic and gastrointestinal cancer (63). It is exclusively eliminated by the kidneys 
(64,65) and closely associated with renal function (62,64–67). In 99mTc-DTPA clearance 
studies, TATI levels rise early with very mild reductions in GFR suggesting it may be a more 
sensitive marker of renal impairment than creatinine. The Y-intercept of reciprocal plots of 
TATI against GFR was close to zero, whereas this was high for other biomarkers including 
β2M, creatinine and cystatin C (64,68,69) suggesting that TATI may have the desirable 
property of having minimal non-renal clearance. Thus, in patients without malignancy, TATI 
exhibits potential characteristics of a potential marker of RRF, although this would require 
further investigation. 
 
Other protein-bound solutes 
 
Uraemic solutes that are bound to plasma proteins are poorly removed by haemodialysis (70). 
Clearance of these protein-bound solutes are mainly dependent on renal function via active 
tubular secretion (71,72). Various protein-bound solutes including indole-acetic acid, hippuric 
acid, indoxyl-sulphate, p-cresol and p-cresylglucoronide demonstrate a similar or closer 
relationship to residual GFR than β2-microglobulin (73). These solutes could potentially be 
utilised to estimate RRF in haemodialysis patients, although there may be significant inter-
individual variation due to dietary differences (74). Mechanisms of their generation and extra-
renal clearance are not well understood. 
 
Use of exogenous filtration markers to measure kidney function 
 
GFR can be measured directly by determining the clearance of an ideal exogenous filtration 
marker. Inulin, a fructose polymer made from the Jerusalem artichoke, is considered the gold 
standard filtration marker since it is freely filtered through the glomerulus, not secreted, 
reabsorbed, or metabolised by the kidneys. It is non-toxic, physiologically inert in humans and 
is exclusively eliminated by glomerular filtration with no apparent extra-renal clearance, 
making it ideal for measuring GFR. The inulin clearance method first described by Homer 
Smith and James Shannon in 1935 (75,76) requires the continuous intravenous infusion of 
inulin and bladder catheterisation together with multiple urine and blood collections to measure 
its renal (urinary) clearance. This method is invasive and impractical and therefore cannot be 
used routinely in clinical practice or in the research setting. 
 
A number of alternative methods have been developed which allow GFR to be determined by 
measuring the disappearance of a suitable injected filtration marker from the plasma over time 
to calculate clearance (plasma clearance). Plasma clearance techniques are utilised routinely 
to measure kidney function (77) particularly in patient groups such as children who have 
variable body composition for which serum markers may not accurately reflect kidney function. 
Although accurate, measuring GFR with exogenous filtration markers remains cumbersome 
due to the necessity for intravenous access and blood sampling. However, since there is a 
need for regular intravenous access in haemodialysis patients as part of routine treatment, 
measuring RRF in dialysis patients with exogenous markers could be an attractive alternative 
option to using blood-based biomarkers to estimate RRF.  
 
Types of exogenous filtration markers 
 
Inulin is considered the gold standard filtration marker but it is expensive and has restricted 
availability (42), thus a number of alternative markers are available (table 2). Both radioactive 
and non-radioactive markers can be used. Radioactive markers that are in routine clinical use 
include 99mTc-diethylenetriamine-pentacetic acid (DTPA), 51Cr-ethylenediaminetetra-acetic 
acid (EDTA) and 125I-iothalamate. All three radiolabelled isotopes are stable compounds and 
easily assayed with predominant renal clearance which makes them suitable filtration 
markers, however all three undergo a small amount of protein binding which leads to a slight 
underestimate of GFR by approximately 10% compared with inulin clearance (78,79).  
 
EDTA is considered the radioisotope of choice as its clearance most closely resembles inulin 
clearance and its use is recommended by the British Nuclear Medicine Society (BNMS) 
(77,80), a recent review by Filler et al summarised studies that compared inulin clearance with 
EDTA,  DTPA and 125I-iothalamate clearance and showed that EDTA clearance had the least 
bias (76). Urinary clearance of EDTA is also closely correlated with inulin clearance in those 
with GFR <15ml/min (81). However, it has been reported that plasma EDTA clearance may 
overestimates its urinary clearance by 0.5-6ml/min (79,81–83), possibly due to extra-renal 
elimination (11), this overestimation is relatively magnified in patients with low GFR (81), which 
would limit the use of EDTA plasma clearance to measure RRF in haemodialysis patients.  
 
In the USA, EDTA is not commercially available and DTPA is the standard tracer used and 
has been recommended to be a suitable alternative tracer to EDTA (77). There are no 
significant differences in plasma clearance between DTPA and EDTA, however similar to 
EDTA, plasma clearance of DTPA exceeds its urinary clearance suggesting there is extra-
renal clearance of this marker (79). For 125I-iothalamate, simultaneous comparative clearance 
studies in patients with stable CKD show that plasma clearance of 125I-iothalamate is 
significantly higher than plasma clearance of EDTA. This difference can be reduced with 
probenecid treatment suggesting significant renal tubular secretion of iothalamate (84). 125I-
iothalamate is therefore not considered an accurate marker of GFR (11). Although all three 
markers are able to measure GFR to certain extent, the major limitation is that all three 
markers are radioactive which precludes their regular use in patients.  
 
Non-radioactive contrast agents such as iohexol have therefore been used for measurement 
of kidney function. Iohexol possesses most of the characteristics required for an ideal filtration 
marker (85) and has the least protein binding out of the fore-mentioned exogenous filtration 
markers (<2%) (76). Plasma clearance of iohexol correlates well with urinary inulin clearance 
and across a wide range of GFRs (86,87). Plasma clearance of iohexhol has been compared 
with KRU in haemodialysis patients to see if iohexol clearance can be used to substitute KRU 
in total (renal and dialyser) Kt/V calculation for assessment of dialysis adequacy (88–90). 
Although urinary clearance of iohexol did not differ significantly from KRU, plasma clearance 
of iohexol was significantly greater than the urinary clearance of iohexol due to the presence 
of extra-renal clearance which has been estimated to be approximately 2-3mL/min (88,90,91). 
This would be insignificant in those with normal renal function but the error introduced by this 
may be unacceptably high in haemodialysis patients who have very low levels of kidney 
function (88). Additionally, there is a risk of allergic reaction to iodine and the incidence of 
adverse reactions with non-ionic, low-osmolality contrast media is reported to be 0.04-0.4% of 
patients and risk of death estimated to be to 1 in 75,000 patients (92). There is also a risk of 
nephrotoxicity in radiocontrast agents which may accelerate loss of RRF, although a small 
study found that repeated weekly small volume iohexol administration over a course 3 weeks 
did not affect RRF (88). 
 
Sinistrin is another exogenous filtration marker which is similar to inulin and is a sugar polymer 
of the fructan group that was first isolated from the bulb of the North African root vegetable 
red squill (Urginea maritima) (93). It shares similar properties to inulin which makes it suitable 
as a marker of GFR and is much easier to handle as unlike inulin, it is easily soluble making 
it more convenient for intravenous injection (94). Measurement of kidney function by 
measuring clearance of sinistrin after a bolus injection has been described (93,95,96). Sinistrin 
is potentially useful exogenous filtration marker which could be used to estimate RRF. Use of 
sinistrin clearance to measure RRF in haemodialysis patients has not been reported to date. 
 
Thus, there are limitations with most of the current available alternative exogenous filtration 
markers which hinders their ability to measure RRF. Use of sinistrin to measure RRF may be 
useful given its similarities to the “gold-standard” marker inulin, although this requires further 
investigation. 
 Methods of calculating GFR from plasma clearance 
 
The disappearance of an exogenously injected filtration marker (which is assumed to undergo 
exclusive elimination by the kidneys) from the plasma can be used to determine GFR. Plasma 
clearance of a filtration marker is typically considered to be biexponential consisting of two 
phases (figure 1) – an initial fast phase as represented by an initial steep slope, signifying 
diffusion of the marker between the intra- and extravascular compartments. During this phase, 
there is a higher rate of clearance due to the temporary high concentration of the marker in 
the intravascular compartment. Following equilibration between the intra- and extravascular 
compartments, rate of clearance falls leading to a shallower slope representing the “late-
phase” or terminal exponential of the plasma curve, clearance during this phase reflects renal 
clearance (97) (figure 1). GFR can be calculated by dividing the administered dose of the 
filtration marker by the area under the curve (AUC) of the filtration marker plasma levels (97–
99):- 
 
𝐺𝐹𝑅 =
𝑄
∫ 𝑃 (𝑡)𝑑𝑡
∞
0
                                                     (1) 
 
Where Q is the administered dose of filtration marker at time = 0 and the denominator is the 
total area under the plasma concentration curve. Although this method accurately depicts the 
clearance of the filtration marker, a major disadvantage is the need for multiple sampling points 
taken after injection making it impractical for clinical use. Methods have been developed to 
estimate clearance that require only two or three blood samples. The is also known as the 
“slope-intercept” method and is a commonly used technique in nuclear medicine GFR 
measurements which study radioisotope plasma clearance (76). This method assumes a one-
compartmental model in which the body is treated as one homogenous volume and mixing of 
the injected tracer occurs instantly. Only the slope of the late phase is necessary to calculate 
clearance reducing the number of blood samples required and typically only 2-3 samples are 
required. Linear regression analysis is carried out on the natural logarithm of the plasma 
concentrations against time to determine the slope and intercept of the late phase. The AUC 
for this line can be calculated using the equation:- 
 
𝐴𝑈𝐶 =  
𝑃0
𝑘
                                                           (2) 
 
Where P0 represents the intercept and k denotes the slope. By substituting equation (2) into 
equation (1). The GFR can be calculated using the slope-intercept method (SI-GFR) with the 
equation: - 
 
𝑆𝐼 − 𝐺𝐹𝑅 =
𝑄 × 𝑘
𝑃0
                                              (3) 
 
The volume of distribution of the filtration marker (VD) can be represented by the amount of 
injected marker divided by concentration of the filtration marker in plasma after injection 
(assuming instantaneous mixing) (P0), thus equation (3) can be re-written as: - 
 
𝑆𝐼 − 𝐺𝐹𝑅 (𝑚𝐿/𝑚𝑖𝑛) =  𝑉𝐷(𝑚𝐿) × 𝑘 (𝑚𝑖𝑛
−1)                        (4)  
 
The GFR is negative because of the negative slope but is reported as positive because only 
the absolute value is required (80,97). However, there are frequent reports that plasma 
clearance consistently overestimates GFR compared with urinary clearance (11) even when 
inulin is used (100). The problem with the slope-intercept method is there is systematic 
overestimation of GFR using this technique since the initial fast-phase of the curve is ignored 
and only data from the late phase of the curve is characterised therefore the assumed plasma 
concentration during the initial fast-phase will be lower than the real ones leading to a smaller 
calculated AUC. This overestimation is less relevant in patients with low renal function (80,97), 
although it can be corrected using the Brӧchner-Mortensen (80,99) or Chantler correction 
(101). Another reason for overestimation of GFR is taking plasma samples too early, sampling 
prior to adequate equilibration of the filtration marker between the intra- and extra-vascular 
compartments leads to underestimation of the half-life of the marker and the AUC causing 
overestimation of GFR (11), thus selection of the optimum sampling time is of critical 
importance, particularly for those with low GFR. Agarwal et al (102) found that GFR over-
estimation using iothalamate clearance can be minimised by prolonging the sampling period 
in those with low GFR (<30 mL/min/1.73m2) by sampling over 9 hours and for those <10 
mL/min/1.73m2, a 15-hour study was recommended (102).  
 
Although these techniques could potentially be applied for the measurement of RRF in 
haemodialysis patients, they are still impractical since it would require a minimum of two blood 
draws within a 24 hour period and extra visits to the hospital. An ideal method of measuring 
RRF would be for a suitable filtration marker to be injected post-dialysis and then its clearance 
measured by a single blood sample taken immediately before the next planned dialysis 
session.  
 Single blood sample methods to measure GFR 
 
A number of equations have been developed which allow GFR to be estimated based on a 
single blood draw after intravenous injection of a filtration marker (103). These methods are 
based on empiric relationships between the apparent distribution volume of the filtration 
marker and various GFR regression equations (97). For adults, the Watson-modified method 
of Christensen and Groth (104,105) is recommended by international guidelines for nuclear 
medicine GFR studies (77), the BNMS have additionally developed a modified equation which 
offers improved accuracy (106). However, both equations have unacceptably high errors in 
those with clearances <30mL/min (80) and are not recommended for those with low GFRs 
(106). One major limitation with guidelines and studies that assess the accuracy of single-
sample equations is that blood sampling time was standardised and fixed to be 2-4 hours after 
tracer injection (80,106). It has been demonstrated that prolonging the sampling time up to 24 
hours or more after tracer injection improves the performance of single-sample equations in 
those with low GFR (107). It is unclear if prolonging the sampling time would sufficiently 
improve the performance of single-sample equations for use in those with advanced kidney 
disease.  
 
In patients with renal failure, the Jacobsson equation (108) is the most commonly evaluated 
single-sample technique (88,90,91,109,110), with attempts to quantify RRF in haemodialysis 
patients reported in two studies (88,90). This method is based on a one-compartment model 
and contains corrections to account for non-immediate mixing and lack of complete uniform 
distribution of the tracer. The accuracy of the equation depends on the how distribution volume 
is calculated and the timing of the blood sample (108). The distribution volume is not measured 
but estimated from anthropometric measures such as body weight which can lead to potential 
errors in estimation of clearance (111), the distribution volume is also dependent of the type 
of tracer used (108). 
 
Single plasma clearance calculated using the Jacobsson formula is given by the equation: - 
 
𝐶𝑙 =  
1
𝑡
𝑉 + 0.0016
 × ln
𝑄
𝑉 × 𝐶𝑡
 
 
Where t is the time interval between injection and sampling (min), V is the volume of 
distribution (mL), Q is the total dose of injected filtration marker and Ct is the concentration of 
the plasma sample at taken at time t. Different authors have used different formulas to 
calculate V (90,91,110), but V is usually calculated as a function of body weight.    
 
In non-dialysed patients with impaired kidney function, plasma clearance calculated using the 
Jacobsson equation correlated strongly with plasma clearance calculated from multiple blood 
samples (91,109,110). However despite the strong correlation, two studies reported that the 
slope of the regression lines for GFR calculated using multiple-sampling and single-point 
sampling deviated significantly from the line of identity suggesting that the two methods are 
significantly different from each other (91,110). In one study, a relatively short sampling time 
of 10 hours was used for clearance calculation for those with low GFR (<40L/min/1.73m2) 
which may partly explain the findings (110). On the contrary, Sterner et al (109) concluded 
that clearance based upon multiple point blood sampling can be substituted with a single-point 
sampling in patients with reduced renal function providing that blood sampling time was 
performed late after iohexol injection (up to 24hours) with selection of sampling time 
depending on level of GFR. The optimum sampling time is dependent on the level of GFR and 
a standardised blood sampling time-point for all patients with no regard for their GFR cannot 
be used.  
 
In haemodialysis patients, Swan et al estimated KRU by administering iohexol at the end of 
dialysis and measuring its clearance using a blood sample taken approximately 44 hours later 
(immediately before the next dialysis session) (88). Correlation between RRF derived from 
single-sample plasma iohexol clearance with KRU was low and overestimated KRU due to 
non-renal clearance of iohexol estimated at ~3ml/min. However, the degree of non-renal 
clearance of iohexol was relatively constant in both oliguric and non-oliguric subjects in this 
study and similar to that reported in other studies [Frennby et al, 2ml/min(91);  Sacamay et al, 
2.97ml/min(90)]. By accounting for non-renal clearance, iohexol-derived RRF did not differ 
from KRU. Another study reached similar conclusions by subtracting non-renal clearance of 
iohexol as a ‘constant’ from the total plasma clearance of iohexol (90). 
 
In conclusion, use of single-sample techniques to measure the plasma clearance of 
exogenous filtration markers is a potential method that can be used to estimate RRF in 
haemodialysis without urine collection. Much work needs to be done before these techniques 
can be used to replace urine collection in the clinical setting. Firstly, the optimal exogenous 
filtration marker to use is unclear, iohexol appears to be the most promising but is limited by 
potential adverse reactions from intravenous administration and the presence of non-renal 
clearance which causes overestimation of RRF. Although the studies completed so far 
suggest a fairly constant rate of non-renal clearance between individuals, further work is 
needed to clarify the inter- and intra-individual variation in non-renal clearance of iohexol. 
Sinistrin, being very similar to inulin may be a better filtration marker to iohexol but its 
metabolism, kinetics and clearance characteristics in haemodialysis patients has not been 
studied. Secondly, although the Jacobsson equation is the most  studied method in patients 
with impaired renal function, many other single-sample equations have been developed and 
it is unknown whether other equations would provide better estimates of RRF. Thirdly, 
estimating volume in haemodialysis patients is difficult due to the fluctuation in hydration status 
and body weight between dialysis sessions which will affect the performance of equations that 
are dependent on accurate volume estimations using anthropometric parameters – 
bioimpedance may have a role in optimising volume estimation and improve the accuracy of 
RRF estimations using single-sample techniques. Finally, from a pragmatic point of view, 
single sample techniques can only be utilised in the clinical setting as long as the optimal 
sampling time does not exceed 44 or 68 hours (after the long inter-dialytic gap), the optimal 
sampling time depends on the type of filtration marker used and also the fluid status of the 
patients. Equilibration of the filtration marker between the intra- and extra-cellular 
compartments is significantly prolonged in overloaded subjects with significant oedema (112), 
it is possible that the optimal sampling time may be >68 hours in very overloaded patients 
leading to errors in GFR estimation using single-sample clearance techniques. The optimal 
sampling time for different filtration markers in haemodialysis patients of varying hydration 
status requires further study. 
 
Novel methods of measuring kidney function 
 
Transcutaneous measurement of GFR using fluorescent tracers 
 
Full measurement of the plasma clearance of a filtration marker requires regular venous 
sampling which is invasive and inconvenient. To overcome this, optical techniques have been 
developed which measure GFR by analysing the disappearance of injected fluorescent tracers 
over time using transcutaneous devices. This technique allows non-invasive, real-time 
monitoring of the elimination kinetics of an injected tracer to measure plasma clearance. These 
methods are currently under development and successful use of fluorescent GFR markers 
including carboystyril124-DTPA-europium and FITC-sinistrin to measure kidney function in 
different animal models have been reported (113–116).  
 
 
Measurement of GFR using finger-prick tests 
 
Similarly, to avoid the need for repeat venous sampling to study plasma clearance of filtration 
markers, analytical techniques have been developed which allow iohexol clearance to be 
measured by using a finger-prick method to collect capillary samples on filter paper for 
analysis. This method showed good correlation and minimal bias compared to iohexol 
clearance using venous sampling (117). Refinement of this technique could allow its 
applicability in haemodialysis patients by allowing patients or carers to collect blood samples 
themselves at home and to be stored for analysis later to measure RRF. 
  
Conclusion 
 
In summary, the measurement of RRF in haemodialysis patients remain challenging and a 
convenient method of quantifying RRF without urine collection continues to elude 
nephrologists. The current reliance on inter-dialytic urine collection for measurement of RRF 
is impractical and is the Achilles’ heel of the incremental haemodialysis regimes given the 
need to measure RRF regularly (118). There have been some success with the use of serum 
biomarkers βTP and β2M to estimate RRF (21,41) especially to determine specific cut-off 
levels of residual urea clearance. Use of exogenous filtration markers to measure RRF have 
shown promise in some studies and filtration markers could conveniently be administered at 
the end of dialysis and its clearance measured using a single pre-dialysis sample immediately 
before the next dialysis session although major limitations needs to be considered before it 
can be applied in the clinical setting.  
Table 1: Blood biomarkers of residual renal function in haemodialysis patients 
Biomarker Molecular weight Examined in 
HD patients? 
Published equations to estimate 
RRF 
 
Limitations for measuring RRF 
Cystatin C 13.3 kDa Yes Hoek et al (20) 
 
𝐺𝐹𝑅 = −0.77 + 21 (
1
𝐶𝑦𝑠𝑡𝑎𝑡𝑖𝑛 𝐶
) 
Levels affected by thyroid dysfunction and 
steroid use 
 
Significant extra-renal clearance 
 
Significant intra- and inter-individual variation in 
cystatin C levels 
 
β2-microglobulin 11.8 kDa Yes Vilar et al (36) 
 
𝐺𝐹𝑅 = 160.3 ×  (
1
𝛽2𝑀
) − 4.2 
 
 
Non-specific elevation with malignancy and 
inflammation 
 
Large inter-individual variation  
 
 
β-trace protein 23-29 kDa Yes Shafi et al (21) 
 
𝐺𝐹𝑅 = 673 ×  𝛽𝑇𝑃−1.406 × 𝛽2𝑀−1.096 × 1.67 𝑖𝑓 𝑚𝑎𝑙𝑒 
 
Wong et al (41) 
 
𝐺𝐹𝑅 =
13.471
𝛽𝑇𝑃
+
52.379
𝛽2𝑀
+
782.909
𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒
+ 0.519 (𝑖𝑓 𝑚𝑎𝑙𝑒)
− 3.939 
 
Requires assay standardisation 
 
Wide limits of agreement of bias when 
compared to urinary urea and creatinine 
creatinine clearances 
Neutrophil gelatinase-
associated lipocalin 
 
 
25 kDa No - Release triggered by systemic inflammation 
and malignancy 
 
NGAL levels differ depending on underlying 
renal pathology independent of GFR 
 
Limited to ELISA-based assays and assays 
require standardisation 
 
Chromogranin A 49 kDa No - Elevated in certain tumours 
 
Probable significant inter-individual variation 
 
Levels are significantly increased with use or 
proton-pump inhibitors 
 
Tumour-associated 
trypsin inhibitor 
6.2 kDa No - Elevated in certain tumours 
 
Relatively small molecule and levels may 
fluctuate significantly between dialysis sessions 
 
Protein-bound solutes  
 
Indole-acetic acid 
Hippuric acid 
Indoxyl-sulphate 
p-cresol 
p-cresylglucorinide 
 
 
 
 
175 Da 
179 Da 
213 Da 
187 Da 
284 Da 
(73) 
No - Possible significant inter-individual variation 
due to dietary differences  
 
Mechanisms of generation and extra-renal 
clearance poorly understood  
 
RRF, residual renal function, kDa, kilodaltons, βTP, β-trace protein; β2M, β2-microglobulin; NGAL, neutrophil gelatinase-associated lipocalin 
  
Table 2: Advantages and limitations of exogenous filtration marker used for GFR measurement using plasma clearance – adapted 
from Filler et al (76) 
Marker 
 
Advantages Limitations 
Radioactive markers 
 
  
99mTc-diethylenetriamine-pentacetic acid (DTPA) Economical 
 
 
 
Unstable chelate and samples require processing 
within 24 hours 
 
Extra-renal clearance leading to overestimation of GFR 
 
10.99±0.68% in-vitro plasma protein binding (119) 
 
51Cr-ethylenediaminetetra-acetic acid (EDTA) Long half-life which permits delayed sample analysis  Not available in USA 
 
Extra-renal clearance leading to overestimation of GFR 
 
12.15±0.59% in-vitro plasma protein binding (119) 
 
125I-iothalamate Can be used as filtration marker without radioactive 
label. Plasma level can be assessed using high-
performance liquid chromatography or X-ray 
fluorescence (11) 
 
Significant overestimation of GFR due to renal tubular 
secretion 
Non-radioactive markers 
 
  
Iohexol Plasma clearance correlates well with urinary inulin 
clearance  
 
Correlates well with RRF measured using urinary urea 
clearance 
 
Minimal in-vitro plasma protein binding – 2%(119) 
 
 
Potential nephrotoxicity 
 
Potential adverse allergic reactions 
Sinistrin Similar properties to the ‘gold-standard’ filtration marker 
inulin 
 
 
 
Kinetic and clearance characteristics  
not thoroughly examined in haemodialysis patients 
 
Isolated reports of anaphylaxis (120,121) 
Figure 1: Schematic diagram to illustrate plasma clearance of exogenously injected 
filtration marker  
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